Phenotypes Associated with This Genotype

Genotype
MGI:4844190

• Allelic Composition: Kras^tm1Bbd/Kras^tm2Bbd; Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd}
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:161780 )

• 50% survival for tamoxifen-treated mice is 25 weeks compared with 42 weeks for similarly treated Kras^tm1Bbd/Kras⁺ Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd} littermates

neoplasm

increased lung tumor incidence ( J:161780 )

• lung tumors in tamoxifen-treated mice are more aggressive than in similarly treated Kras^tm1Bbd/Kras⁺ Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd} mice

• however, treatment with the Cdk4 inhibitor PD0332991 reduces tumor formation

increased lung non-small cell carcinoma incidence ( J:161780 )

• in mice treated with tamoxifen

cellular

increased cell proliferation ( J:161780 )

• proliferation of lung cells in tamoxifen-treated mice exhibit 8- to 10-fold greater proliferation than in Cdk4^tm2.1Bbd/Cdk4^tm2.1Bbd Kras^tm1Bbd/Kras^tm2Bbd Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd} mice

respiratory system

increased lung tumor incidence ( J:161780 )

• lung tumors in tamoxifen-treated mice are more aggressive than in similarly treated Kras^tm1Bbd/Kras⁺ Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a^{tm1(cre/ERT2)Bbd} mice

• however, treatment with the Cdk4 inhibitor PD0332991 reduces tumor formation

increased lung non-small cell carcinoma incidence ( J:161780 )

• in mice treated with tamoxifen

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:161780